Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RT001 for Lateral Canthal Lines
NCT00888914Phase 2Completed
- Sponsor
- Revance Therapeutics
- Start
- Nov 2008
- Primary completion
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of RT001 in lateral canthal rhytides (5 arms), sponsored by Revance Therapeutics. Primary endpoint: Investigator Global Assessment at Smile at Day 28. Started Nov 2008; status: completed.
02
Drugs
RT001
03
Conditions
lateral canthal rhytides
Beyond the preview
Go deeper on NCT00888914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00888914.